GlassScriptPhysician profile
Deborah R Flomenhoft
NPI 1619039781
$18,302.67
in general payments reported to CMS, 2019-2025
11 companies · $3,551 in 2025
The $3,551 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $7,488 · 2023: $169 · 2024: $7,094 · 2025: $3,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,290 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Travel and Lodging: $574 · Food and Beverage: $552 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,290.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Travel and Lodging | $574.46 |
| Food and Beverage | $552.49 |
| Education | $247.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $7,377.20 | 2022-2023 | Stelara |
| Janssen Global Services, LLC | $7,004.46 | 2024 | Tremfya |
| Janssen Biotech, INC. | $3,681.62 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $82.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Axonics, INC. | $58.04 | 2023 | Axonics |
| Pfizer INC. | $30.00 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Flomenhoft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.